Parkinson's Disease Psychosis

Neurology
7
Pipeline Programs
1
Companies
6
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
4
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Acadia Pharmaceuticals
NUPLAZIDApproved
pimavanserin tartrate
Acadia Pharmaceuticals
oral2016
U
PIMAVANSERINApproved
pimavanserin tartrate
Unknown Company
oral2024

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Acadia Pharmaceuticals
6 programs
1
4
1
Pimavanserin tartratePhase 31 trial
Pimavanserin tartratePhase 31 trial
Pimavanserin tartratePhase 31 trial
pimavanserin tartratePhase 31 trial
pimavanserin tartratePhase 21 trial
+1 more programs
Active Trials
NCT02762591Approved For Marketing
NCT01518309Completed39Est. May 2013
NCT00658567Completed123Est. Dec 2009
+3 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acadia Pharmaceuticalspimavanserin tartrate
Acadia PharmaceuticalsPimavanserin tartrate
Acadia PharmaceuticalsPimavanserin tartrate
Acadia PharmaceuticalsPimavanserin tartrate
Acadia Pharmaceuticalspimavanserin tartrate

Clinical Trials (6)

Total enrollment: 1,118 patients across 6 trials

NCT01174004Acadia Pharmaceuticalspimavanserin tartrate

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Start: Jul 2010Est. completion: Nov 2012199 patients
Phase 3Completed
NCT00658567Acadia PharmaceuticalsPimavanserin tartrate

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Mar 2008Est. completion: Dec 2009123 patients
Phase 3Completed
NCT00550238Acadia PharmaceuticalsPimavanserin tartrate

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Jul 2007Est. completion: May 2018459 patients
Phase 3Completed
NCT00477672Acadia PharmaceuticalsPimavanserin tartrate

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Start: Jun 2007Est. completion: Jul 2009298 patients
Phase 3Completed
NCT01518309Acadia Pharmaceuticalspimavanserin tartrate

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Start: Nov 2004Est. completion: May 201339 patients
Phase 2Completed
NCT02762591Acadia PharmaceuticalsPimavanserin tartrate

Expanded Access of Pimavanserin for Patients With PD Psychosis

N/AApproved For Marketing

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)